End-of-day quote
OTC Markets
03:30:00 04/04/2024 am IST
|
5-day change
|
1st Jan Change
|
0.11
USD
|
-.--%
|
|
-.--%
|
+10.00%
|
Fiscal Period: December |
2021
|
2022
|
---|
Capitalization
1 |
80
|
27.36
|
Enterprise Value (EV)
1 |
77.77
|
27.34
|
P/E ratio
|
-17.8
x
|
-9.17
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
EV / Revenue
|
-
|
-
|
EV / EBITDA
|
-2,35,32,521
x
|
-93,51,910
x
|
EV / FCF
|
-9,46,59,106
x
|
-2,60,30,617
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
36.5
x
|
-111
x
|
Nbr of stocks (in thousands)
|
74,762
|
74,762
|
Reference price
2 |
1.070
|
0.3660
|
Announcement Date
|
31/03/22
|
31/03/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
EBITDA
|
-
|
-3.399
|
-2.926
|
EBIT
1 |
-36.68
|
-3.428
|
-2.935
|
Operating Margin
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-36.68
|
-4.332
|
-2.986
|
Net income
1 |
-36.68
|
-4.332
|
-2.986
|
Net margin
|
-
|
-
|
-
|
EPS
2 |
-0.8996
|
-0.0601
|
-0.0399
|
Free Cash Flow
|
-
|
-0.8451
|
-1.051
|
FCF margin
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
29/06/21
|
31/03/22
|
31/03/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
2.23
|
0.02
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-0.85
|
-1.05
|
ROE (net income / shareholders' equity)
|
-
|
-432%
|
-307%
|
ROA (Net income/ Total Assets)
|
-
|
-168%
|
-140%
|
Assets
1 |
-
|
2.586
|
2.13
|
Book Value Per Share
2 |
-0
|
0.0300
|
-0
|
Cash Flow per Share
|
-
|
0.0300
|
0
|
Capex
|
-
|
0.04
|
-
|
Capex / Sales
|
-
|
-
|
-
|
Announcement Date
|
29/06/21
|
31/03/22
|
31/03/23
|
|
1st Jan change
|
Capi.
|
---|
| +10.00% | 8.22M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +28.07% | 12.14B | | +0.17% | 12.15B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|